Loading
A phase 3 trial of Izalontamab brengitecan, Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08) is a phase 3 interventional study registered as NCT07640789 by Sichuan Baili Pharmaceutical Co., Ltd., with 418 participants planned, started 2026-08-28 and due to reach its primary completion in 2030-12. Interventions recorded: BL-B01D1, Osimertinib. Conditions listed: Non-small Cell Lung Cancer Stage III. No results are recorded here; the registry entry is the source.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Osimertinib, EGFR-mutated non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Osimertinib, Small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Osimertinib, Small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Osimertinib, EGFR-mutated non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.